Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-124 Evuzamitide for Diagnosis of Cardiac Amyloidosis
NCT06788535Phase 3Completed
- Start
- Jan 2025
- Primary completion
- Apr 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of 124I-evuzamitide in cardiac amyloidosis. Primary endpoints: Sensitivity for diagnosing cardiac amyloidosis at 60 days and Specificity for diagnosing cardiac amyloidosis at 60 days. Started Jan 2025; status: completed.
02
Drugs
124I-evuzamitide
03
Conditions
cardiac amyloidosis
Beyond the preview
Go deeper on NCT06788535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06788535.